Serum can inhibit reversal of multidrug resistance by chemosensitisers

European Journal of Cancer

Volumn 32, Issue 5, 1996, Pages 862-867

  Lehnert, M ^a   De Giuli, R ^a   Kunke, K ^b   Emerson, S ^b   Dalton, W S ^b   Salmon, S E ^b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Chemosensitisers; Multidrug resistance; Serum inhibition

Indexed keywords

AMIODARONE; CHEMOSENSITIZING AGENT; CYCLOSPORIN A; DOXORUBICIN; MEDROXYPROGESTERONE ACETATE; QUINIDINE; QUININE; TAMOXIFEN; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; DRUG INACTIVATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MYELOMA CELL; PRIORITY JOURNAL; SERUM;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CATTLE; CELL DEATH; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HORSES; HUMANS; TUMOR CELLS, CULTURED;

EID: 0029980875     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00004-4     Document Type: Article

References (41)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62, 385-427.
2. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81, 116-124.
3. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87, 7160-7164.
4. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993, 81, 2215-2222.
5. Chan HSL, Thorner PS, Haddad G, et al. Immunohistochemical detection of P-glycoprotein. Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990, 8, 689-704.
6. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991, 325, 1608-1614.
7. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 42, 155-199.
8. Salmon SE, Dalton WS, Grogn TM, et al. Multidrug-resistant myeloma. Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991, 78, 44-50.
9. Miller TP, Grogan TM, Dalton WS, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991, 9, 17-24.
10. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma with cyclosporin. Lancet 1992, 340, 255-259.
11. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993, 11, 1652-1660.
12. Wishart GC, Bissett D, Paul J, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer. Mature results of a placebo-controlled randomized trial. J Clin Oncol 1994, 12, 1771-1777.
13. Solary E, Caillot D, Chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992, 10, 1730-1736.
14. Van der Graaf WTA, de Vries EGE, Uges DRA, et al. In vitro and in vivo modulation of multi-drug resistance with amiodarone. Int J Cancer 1991, 48, 616-622.
15. Miller RL, Bukowski RM, Budd GT, et al. Clinical modulation of doxorubicin resistance by the calmodulin inhibitor, trifluoperazine. A phase I/II trial. J Clin Oncol 1988, 83, 105-110.
16. Millward MJ, Cantwell BMJ, Lien EA, et al. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992, 28A, 805-810.
17. Sikic BI. Modulation of multidrug resistance. At the threshold. J Clin Oncol 1993, 11, 1629-1636.
18. Lehnert M. Reversal of P-glycoprotein-associated multidrug resistance. The challenge continues. Eur J Cancer 1993, 29A, 636-638.
19. Dalton WS, Durie BGM, Alberts DS, et al. Characterization of a new drug-resistant human myeloma cell that expresses P-glycoprotein. Cancer Res 1986, 46, 5125-5130.
20. Dalton WS, Grogan TM, Rybski JA, et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells. Association with level of drug resistance and drug accumulation. Blood 1989, 73, 747-752.
21. Chen TR. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 1977, 104, 255-262.
22. Woodcock DM, Jefferson S, Linsenmeyer ME, et al. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990, 50, 4199-4203.
23. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science (Wash, DC) 1977, 197, 461-463.
24. Salmon SE, Young L, Leibowitz J, et al. Evaluation of an automated image analysis system for counting human tumor colonies. Int J Cell Cloning 1984, 2, 142-160.
25. Speth PAJ, Linssen PCM, Boezeman JBM, et al. Quantification of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography. Cytometry 1985, 6, 143-150.
26. Becker RA, Chambers JM, Wilks AR. The New S Language. Pacific Grove, Wadsworth & Brooks/Cole, 1988.
27. Lehmann EL. Theory of Point Estimation. New York, Wiley, 1983.
28. Billingsley P. Probability and Measure, 2nd edn. New York, Wiley, 1986.
29. Rosner B. Fundamentals and Biostatistics, 3rd edn. Boston, PWS-Kent, 1990.
30. Chatterjee M, Robson CN, Harris AL. Reversal of multidrug resistance by verapamil and modulation by α1-acid glycoprotein in wild-type and multidrug-resistant chinese hamster ovary cell lines. Cancer Res 1990, 50, 2818-2822.
31. Freedberg KA, Innis RB, Creese I, et al. Anti-schizophrenic drugs - differential plasma protein-binding and therapeutic activity. Life Sci 1979, 24, 2467-2473.
32. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984, 9, 136-156.
33. Vozeh S, Schmidlin O, Taeschner W. Pharmacokinetic drug data. Clin Pharmacokinet 1988, 15, 254-282.
34. Keefe DL, Yee YG, Kates RE. Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther 1981, 29, 21-26.
35. Lindup WE. Plasma protein binding of drugs - some basic and clinical aspects. In Bridges JW, Chasseaud LF, Gilson GG, eds. Progress in Drug Metabolism. London, Taylor & Francis Ltd, 1987, 141-185.
36. Jahnchen W, Muller WE. Stereoselectiviry in protein binding and drug deposition. In Breimer DD, Speiser P, eds. Topics in Pharmaceutical Sciences. New York, Elsevier Science, 1983, 109-117.
37. Broxterman HJ, Kuiper CM, Schuurhuis GJ, et al. Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs. Role of protein binding. Cancer Lett 1987, 35, 87-95.
38. Gene P, Dimanche-Biotrel MT, Mauvernay RY, et al. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer Res 1992, 52, 2797-2801.
39. 1 acid glycoprotein. Eur J Cancer 1990, 26, 432-436.
40. Pennock GD, Dalton WS, Roeske WR, et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991, 83, 105-110.
41. Hofheinz W, Merkli B. Quinine and quinine analogues. In Peters W, Richards WHG, eds. Antimalarial Drugs II, Current Antimalarials and New Drug Developments. Berlin, Springer, 1984, 61-81.